Registered title, quoted from ClinicalTrials.gov
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 10 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 10
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
- Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
- Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
- Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05722275, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
(1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound;
Inclusion criterion 1
(4) without other evidence of distant metastasis, and no stage IV features on CT.
Inclusion criterion 4
(1) previous abdominal surgery;
Exclusion criterion 1
(2) with both enhanced CT and laparoscopy;
Inclusion criterion 2
(3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement);
Inclusion criterion 3
(3) time intervals between CT and laparoscopy longer than 2 weeks;
Exclusion criterion 3
(4) CT image artifacts that undermine peritoneal lesion assessment.
Exclusion criterion 4
(2) previous abdominal malignancies or inflammatory diseases;
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05722275, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound;
- (2) with both enhanced CT and laparoscopy;
- (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement);
- (4) without other evidence of distant metastasis, and no stage IV features on CT.
Exclusion Criteria:
- (1) previous abdominal surgery;
- (2) previous abdominal malignancies or inflammatory diseases;
- (3) time intervals between CT and laparoscopy longer than 2 weeks;
- (4) CT image artifacts that undermine peritoneal lesion assessment.
Quoted from ClinicalTrials.gov, NCT05722275, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05722275, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.